Prospective study explores imaging screening outcomes for advanced HER2-positive and triple-negative breast cancer, suggesting clinical application in treatment decisions.
We would like to thank Nimura et al. for their careful reading of our study1 and for their two important comments2 regarding treatment decision-making and neurocognitive evaluation. We agree that the landscape of brain metastasis (BM) management is rapidly evolving, and their comments raise important points about how to apply our findings to current clinical practice.
No takes yet. Share an insight, caveat, or question.
Kim et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: